Overview
On 7 March 2005, orphan designation (EU/3/05/261) was granted by the European Commission to Bausch & Lomb (UK) Ltd, United Kingdom, for fluocinolone acetonide (prolonged-release intravitreal implant) for the treatment of non-infectious uveitis affecting the posterior segment of the eye.
The sponsorship was transferred to Bausch & Lomb Ireland in October 2006.
Key facts
Active substance |
Fluocinolone acetonide
|
Intended use |
Treatment of non-infectious uveitis affecting the posterior segment of the eye
|
Orphan designation status |
Positive
|
EU designation number |
EU/3/05/261
|
Date of designation |
07/03/2005
|
Sponsor |
Bausch & Lomb Ireland
IDA Industrial Park Waterford Ireland Telephone: + 353 51 35 501 Telefax: + 353 51 35 56 39 E-mail: waterfordinfo@bausch.com |
Patients' organisations
For contact details of patients’ organisations whose activities are targeted at rare diseases, see:
EU register of orphan medicines
The list of medicines that have received an orphan designation in the EU is available on the European Commission's website: